This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| TPMT | |
|---|---|
| Name | Thiopurine S-methyltransferase |
| Organism | Human |
| Ec number | 2.1.1.67 |
TPMT
Thiopurine S-methyltransferase is an enzyme that catalyzes S-methylation reactions relevant to thiopurine metabolism and is clinically important in oncology and Hematology-related therapeutics. Discovered through biochemical studies associated with adverse reactions to azathioprine, mercaptopurine, and thioguanine, it links observed pharmacovigilance in World Health Organization programs to molecular genetics investigated by groups at institutions such as National Institutes of Health and Mayo Clinic. Clinical guidelines from organizations like the Clinical Pharmacogenetics Implementation Consortium and regulatory agencies including the European Medicines Agency and Food and Drug Administration incorporate enzyme activity stratification into therapeutic decision-making.
The enzyme is a cytosolic methyltransferase with a molecular architecture determined by crystallographic and spectroscopic studies from teams at the European Molecular Biology Laboratory and the Max Planck Society. It uses S-adenosyl-L-methionine as a methyl donor, linking biochemical pathways mapped in KEGG and structural databases curated by UniProt and the Protein Data Bank. The catalytic mechanism involves nucleophilic attack on thiopurine substrates and has been characterized alongside related methyltransferases studied in laboratories at Imperial College London and Johns Hopkins University. Comparative enzymology places it in context with enzymes investigated at the Wellcome Trust Sanger Institute and centers focused on xenobiotic metabolism such as the National Institute of Environmental Health Sciences.
Genetic variation in the coding gene is extensively characterized in population genetics studies from consortia including the 1000 Genomes Project and the HapMap Project. Allelic variants were cataloged in sequencing efforts by research groups at Harvard Medical School and the Broad Institute, revealing nonsynonymous single-nucleotide polymorphisms that produce low-activity or null alleles described in clinical reports from Mayo Clinic case series and cohort studies at University College London. Pharmacogenomic databases maintained by organizations such as the PharmGKB and the European Bioinformatics Institute aggregate genotype–phenotype associations, while epidemiological surveys from centers like the Centers for Disease Control and Prevention compare variant frequencies across populations studied in projects associated with the Human Genome Project.
Genotype-guided dosing recommendations were developed through collaborative networks including the Clinical Pharmacogenetics Implementation Consortium and evidence syntheses by panels convened at the Royal College of Physicians and the American College of Medical Genetics and Genomics. Diagnostic testing is offered by commercial laboratories accredited by bodies such as the College of American Pathologists and national health services like the National Health Service (England), using genotyping and phenotyping assays validated in studies published in journals associated with the American Society of Hematology and the European Society for Medical Oncology. Implementation research involving health technology assessment agencies including the National Institute for Health and Care Excellence studies cost-effectiveness and clinical utility across settings modeled in trials at institutions such as Vanderbilt University Medical Center.
Thiopurine drugs, used in treatment protocols developed at centers like Memorial Sloan Kettering Cancer Center and therapeutic regimens from the World Health Organization essential medicines lists, require individualized dosing when enzyme activity is reduced. Clinical trials led by investigators at St. Jude Children’s Research Hospital and multicenter oncology groups such as the European Organisation for Research and Treatment of Cancer have demonstrated altered pharmacokinetics and increased myelotoxicity in patients with variant alleles. Guidelines from the British Society for Haematology and pediatric oncology networks recommend preemptive testing to adjust dosing in protocols similar to those practiced at Children's Hospital of Philadelphia.
Reduced or absent enzyme activity is associated with hematologic toxicity, pancreatitis risk profiles described in case series from Johns Hopkins Hospital and bleeding complications reported in registries managed by the National Cancer Institute. Risk mitigation strategies include dose reduction algorithms and therapeutic drug monitoring coordinated by pharmacists trained in programs at University of California, San Francisco and clinical pharmacists affiliated with the American Society of Health-System Pharmacists. Regulatory safety communications from the Food and Drug Administration and pharmacovigilance activities by the European Medicines Agency recommend informed consent and patient education modeled on frameworks developed by the World Health Organization patient safety initiatives.
Ongoing research integrates enzyme pharmacogenetics into precision medicine frameworks promoted by initiatives at the National Institutes of Health All of Us Research Program and translational studies at the Broad Institute combining genomics, transcriptomics, and metabolomics. Novel therapeutic strategies, including combination regimens evaluated by researchers at Dana-Farber Cancer Institute and gene-editing approaches investigated at Massachusetts Institute of Technology, explore ways to modulate thiopurine response. International collaborations—such as consortia linking the Wellcome Trust with academic centers in Japan and Australia—continue to expand variant annotation, population screening, and clinical implementation science.
Category:Human enzymes